Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: Hank who wrote (1798)	12/5/1999 9:23:00 PM
From: DanZ	Read Replies (1) \| Respond to of 5582

<Then whey did the FTC refer to the Quigley studies as "bad science"?> Say what??? The FTC made no such quote and didn't even imply "bad science". Please point me to a link that backs up your claim. This is what Quigley's press release said: The Quigley Corporation <QGLY.O>, which makes and markets Cold-Eeze brand zinc lozenges, has agreed not to claim they can prevent colds, reduce the risk of pneumonia, fight allergies and ease cold symptoms in children, the FTC said. The settlement does not impact the company's primary claim that Cold-Eeze can reduce the severity and duration of cold symptoms in adults, FTC and company officials said. _____ The FTC took this action because Quigley made claims on QVC that Cold Eeze prevents colds, reduces the risk of pneumonia, fights allergies, and eases cold symptoms in children. Their clinical studies did not address these issues.